[Asia Economy Reporter Hyungsoo Park] Etron, EID, and Ewha Electric are showing strong performance. The news that the Russian-made COVID-19 vaccine Sputnik V has strong preventive effects against the India-originated Delta variant appears to have influenced stock prices.
As of 9:16 AM on the 30th, Etron is trading at 866 KRW, up 9.21% from the previous day. EID and Etron are also showing strength.
According to foreign media, Denis Logunov, Deputy Director of Russia's Gamaleya National Research Center for Epidemiology and Microbiology, which developed Sputnik V, stated on the 29th (local time), "The Sputnik V vaccine showed about 90% preventive effectiveness against the Delta variant."
Deputy Director Logunov, one of the key figures leading the development of the Sputnik V vaccine, received a national award on the 9th by special order of Russian President Vladimir Putin.
Korea Corus consortium companies including Korea Corus, Isu Abxis, Binex, Chong Kun Dang Bio, Quratis, and Boryung Biopharma will additionally produce Sputnik Light through existing Sputnik V production facilities. Sputnik Light uses a human adenovirus vector similar to Janssen and is known to provide about 80% preventive effectiveness with a single dose.
Sputnik Light's storage temperature is easily managed at 2?8 degrees Celsius, and the price per single dose is under 10 USD, making it affordable. To achieve herd immunity quickly, the single-dose Sputnik Light vaccine is advantageous. Since production volume is about four times higher than Sputnik V using the same facilities, it is evaluated to have good efficiency and profitability.
Investment returns for Etron and EID, which invested about 20 billion KRW in Korea Corus, are also expected to increase. Etron and EID hold indirect shares in Korea Corus through PEF investment methods, having invested in the second half of last year. Korea Corus is planning to go public next year with Kiwoom Securities as the lead underwriter.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
